Pre-Congress Workshop 2: Designing Human Intervention Studies to Prevent Osteoarthritis After Knee Injury: An Interdisciplinary Workshop
Date/Time: Friday, March 17, 2023 - 10:00 AM to 12:30 PM
Log in to Add to My Schedule
Preventing Post-Traumatic OA Illness and Disease: Vision and Challenges
What Is Post-Traumatic Osteoarthritis, Who Develops It and What Is the Goal of An Intervention?
Dr. Jackie Whittaker, The University of British Columbia, Canada
Defining the Best Outcome Measures, Their Timing and Relationships: Symptoms, Structure and Molecules
Prof. Stefan Lohmander, Lund University, Sweden
Bridging the Gap to Clinical Trials
Considerations for Post-Traumatic Osteoarthritis: A Regulatory Perspective
Dr. Lee Simon, SDG LLC, USA
Can Pre-Clinical Models and Experimental Medicine Studies Help Intervention Selection and Trial Design?
Dr. Nicole Gerwin, Novartis, Switzerland
From Around the (Real) World: Current Examples of Trials, Their Interventions and Comparators
Dr. Adam Culvenor (SUPER-KNEE), La Trobe University, Australia
Prof. Duncan Meuffels (ROTATE-Trial, COMPARE), Erasmus MC, Netherlands
Prof. David Felson (PIKASO Trial), Boston University, USA
1. Learn about the unmet clinical needs in the period between knee injury and early post-traumatic knee osteoarthritis (PTOA)
2. Synthesise the current views on the definition of PTOA
3. Overview of the different possible aims for interventional studies in this area, from preventing symptoms and structural change after a knee injury to validating new targets and surrogate endpoints
4. Outline different outcome measures that might be applied in different types of studies and the knowledge gaps in this area.
5. Understand challenges and overarching considerations for approaches to trial design in this area.
6. Improve knowledge of international efforts (including multicentre studies, networks, and ‘trial banks’) in this area across different intervention types (i.e. physical therapy, surgical, pharmacological)
7. Show awareness of key stakeholders in this area (e.g., patients, clinicians, pre-clinical modelers, pharmaceutical companies, and regulatory bodies) 8. Consider the key priorities for research to enable progress